← Back to Search

Anti-inflammatory agent

Colchicine for Atrial Fibrillation (COP-AF Trial)

Phase 3
Waitlist Available
Led By David Conen, MD, MPH
Research Sponsored by Population Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days of randomization
Awards & highlights

COP-AF Trial Summary

This trial will assess whether the administration of oral colchicine will reduce the incidence of perioperative atrial fibrillation in patients undergoing major thoracic surgery.

Eligible Conditions
  • Atrial Fibrillation
  • Atrial Flutter
  • Myocardial Injury

COP-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days of randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days of randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinically important perioperative atrial fibrillation/atrial flutter
Myocardial Reperfusion Injury
Secondary outcome measures
Duration of stay in ICU, step-down, and in-hospital
First occurrence of myocardial infarction
Myocardial Infarction
+3 more
Other outcome measures
Non-infectious diarrhea
Communicable Diseases

Side effects data

From 2021 Phase 4 trial • 280 Patients • NCT01709981
1%
Chest pain
1%
Ischemic stroke
100%
80%
60%
40%
20%
0%
Study treatment Arm
Colchicine
Placebo

COP-AF Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ColchicineExperimental Treatment1 Intervention
Participants received over-encapsulated colchicine 0.5 mg tablet orally twice daily for 10 days.
Group II: PlaceboPlacebo Group1 Intervention
Participants received matching placebo capsules orally twice daily for 10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Colchicine
2020
Completed Phase 4
~15330

Find a Location

Who is running the clinical trial?

Hamilton Health Sciences CorporationOTHER
365 Previous Clinical Trials
297,594 Total Patients Enrolled
11 Trials studying Atrial Fibrillation
10,078 Patients Enrolled for Atrial Fibrillation
Population Health Research InstituteLead Sponsor
154 Previous Clinical Trials
676,603 Total Patients Enrolled
30 Trials studying Atrial Fibrillation
49,093 Patients Enrolled for Atrial Fibrillation
David Conen, MD, MPHPrincipal InvestigatorPopulation Health Research Institute
1 Previous Clinical Trials
2,800 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
2,800 Patients Enrolled for Atrial Fibrillation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there a lot of medical facilities conducting this clinical trial in Canada?

"This trial is being conducted by the Institut universitaire de cardiologie et de pneumologie de Québec, the CIUSSS de l'Estrie - CHUS, and St. Joseph's Healthcare Hamilton as well as 17 other research facilities."

Answered by AI

What are some of the known risks associated with Colchicine?

"Colchicine efficacy has been supported by some data, while there have been multiple reports affirming its safety. Consequently, our team has given it a score of 3."

Answered by AI

How many people are currently enlisted in this trial?

"That is accurate. The information available on clinicaltrials.gov suggests that this study is still seeking participants. This clinical trial was first posted on February 14th, 2018 and was last edited on November 3rd, 2022. They are recruiting for 3200 participants across 17 locations."

Answered by AI

For what purpose is Colchicine most commonly prescribed?

"gout flares are often best managed through Colchicine medication. However, Colchicine can also be taken to help with conditions such as behcet's syndrome, postcommissurotomy syndrome, and familial mediterranean fever."

Answered by AI

What is the general scientific consensus on Colchicine's efficacy?

"Dr. Hamid Ahmadieh first studied colchicine in 2006. Since that time, 18,334 clinical trials have been completed with colchicine. As of now, there are 32 active trials involving colchicine, a majority of which are located in Québec, Quebec."

Answered by AI
~453 spots leftby Mar 2025